

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
SCOPE OF REPORT.....	1
INTENDED AUDIENCE.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ABOUT THE AUTHOR.....	2
RELATED BCC REPORTS.....	2
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	3
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 4
EXECUTIVE SUMMARY.....	4
EXECUTIVE SUMMARY (CONTINUED).....	5
EXECUTIVE SUMMARY (CONTINUED).....	6
EMERGING BBB TECHNOLOGY MARKET.....	7
EMERGING BBB TECHNOLOGY MARKET (CONTINUED).....	8
KEY DRIVERS.....	9
KEY CHALLENGES.....	10
MAJOR TRENDS.....	11
<i>SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2015 (\$ MILLIONS)</i>	12
<i>SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2015 (\$ MILLIONS)</i>	12
 CHAPTER THREE: OVERVIEW.....	 13
TODAY'S PHARMA MARKET.....	13
<i>FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, BY REGION, 2009 AND 2015 (PERCENT OF GLOBAL SALES)</i>	14
<i>FIGURE 2 EMERGING MARKETS' GROWTH IN PHARMACEUTICAL SALES, 2015 (ESTIMATED \$ BILLIONS)</i>	15
TODAY'S PHARMA MARKET (CONTINUED).....	16
<i>FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION, 2015* (\$ MILLIONS)</i>	17
BIOLOGICS.....	18
<i>FIGURE 4 INVESTMENT IN BIOLOGICS AS A PERCENTAGE OF TOTAL R&D, 2009 (PERCENT OF TOTAL R&D)</i>	18
BIOLOGICS (CONTINUED).....	19
GENERICS SIGNAL NEED FOR INNOVATION.....	20
NEUROFOCUSING IN THE PHARMA INDUSTRY.....	20
<i>FIGURE 5 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2009 (\$ BILLIONS)</i>	21

<i>FIGURE 5 (CONTINUED)</i>	22
<i>FIGURE 6 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2015 AND 2017 (NUMBER OF UNITS)</i>	22
<i>FIGURE 6 (CONTINUED)</i>	23
<i>FIGURE 7 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY INDICATION, 2015 AND 2017 (NUMBER OF UNITS PER INDICATION)</i>	23
<i>FIGURE 7 (CONTINUED)</i>	24
NEUROFOCUSING IN THE PHARMA ... (CONTINUED).....	25
<i>TABLE 1 TOP PHARMA COMPANIES BY REVENUE, 2009 (\$ BILLIONS)</i>	26
EMERGING BBB TECHNOLOGY MARKET.....	26
BRIEF HISTORY OF BBB.....	27
BLOOD BRAIN BARRIER DEFINED.....	28
BBB COMPONENTS.....	29
<i>FIGURE 8 PARTS OF THE BBB</i>	30
BBB ILLUSTRATED.....	30
MAIN AREAS OF THE BRAIN	31
<i>FIGURE 9 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS</i>	31
TREATING DISEASE AND THE BBB	32
MENINGITIS	33
MULTIPLE SCLEROSIS (MS).....	33
ENCEPHALITIS	34
ALZHEIMER'S DISEASE (AD).....	34
PARKINSON'S DISEASE (PD).....	35
BBB TECHNOLOGY CLASSIFICATION.....	36
MOST COMMON BBB TECHNOLOGY	37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED.....	38
TRANSPORT CONSIDERATIONS	39
BYPASSING THE BBB	39
BBB TECHNOLOGY DETAILED	40
CHEMICAL TRANSPORT SYSTEMS.....	40
BIOLOGICAL CARRIER OR TRANSPORT SYSTEMS	40
PHYSICAL FORCE (ENERGETIC) OPENING THROUGH SOUND WAVES (TARGETED ULTRASOUND).....	41
Physical Force (Energetic) Opening...(Continued)	42
<i>FIGURE 10 METHODS OF CROSSING THE BBB</i>	43
ENHANCING BIOLOGICAL TRANSPORT SYSTEM TECHNIQUES	44
NANOPARTICLES AND LIPOSOMES.....	44
NANOPARTICLES	44
<i>TABLE 2 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY</i>	45

Challenges with Nanoparticles	46
Liposomes.....	47
Liposomes (Continued)	48
PATENTS AND INTELLECTUAL PROTECTION	49
<i>TABLE 3 KEY BBB TECHNOLOGY PATENTS.....</i>	<i>49</i>
PATENTS AND INTELLECTUAL (CONTINUED).....	50
ARMAGEN’S PATENT ESTATE	51
ArmaGen’s Patent Estate (Continued)	52
LIFE AFTER PATENTING	53
<i>TABLE 4 SAMPLE OF 2010 FINANCIAL DEALS IN CNS</i>	
<i>THERAPEUTICS.....</i>	<i>54</i>
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE	55
<i>TABLE 5 SAMPLE OF 2010 FINANCIAL DEALS IN BBB</i>	
<i>TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL</i>	
<i>COMPANY (ESTIMATED, \$ MILLIONS)</i>	<i>55</i>
<i>FIGURE 11 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY</i>	
<i>TECHNOLOGY TYPE IN THE DEVELOPMENT PIPELINE, 2010*</i>	
<i>(%).....</i>	<i>56</i>
<i>FIGURE 12 COMPOSITION OF BBB TECHNOLOGY BY</i>	
<i>TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC</i>	
<i>DRUG) MARKET, 2015 (%).....</i>	<i>57</i>
BBB TECHNOLOGY MARKET:... (CONTINUED).....	58
<i>FIGURE 13 DRUGS IN DEVELOPMENT USING BBB-PASSAGE</i>	
<i>TECHNOLOGY, 2010 AND 2015 (NUMBER OF UNITS).....</i>	<i>59</i>
<i>TABLE 6 BBB TECHNOLOGY COMPANIES AND RESPECTIVE</i>	
<i>TECHNOLOGICAL METHODOLOGY</i>	<i>60</i>
<i>TABLE 7 BBB TECHNOLOGY COMPANIES AND CORPORATE</i>	
<i>PARTNERS/LICENSEING DEAL WITH LEAD DISEASE TARGET.....</i>	<i>61</i>
GENZYME INNOVATES IN-HOUSE	61
DRUG DEVELOPMENT IN THE CNS	62
MULTIPLE MODELS MUST BE USED	63
BBB IS ITS OWN SITE OF INVESTIGATION.....	63
BBB is its Own Site of Investigation (Continued).....	64
UNDERSTANDING INTERACTIONS AND BRAIN AREAS AS	
DISTINCT	65
<i>TABLE 8 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING</i>	
<i>BBB TECHNOLOGIES</i>	<i>66</i>
<i>TABLE 8 (CONTINUED).....</i>	<i>67</i>
WHAT VALUES ARE BEST?.....	67
<i>TABLE 9 FREQUENT DRUG DEVELOPMENT CHALLENGES AND</i>	
<i>THEIR CLINICAL EFFECTS.....</i>	<i>68</i>
PROMISING RESEARCH.....	69
PROMISING RESEARCH (CONTINUED)	70
PROMISING RESEARCH (CONTINUED)	71

PROMISING RESEARCH (CONTINUED)	72
PROMISING CNS DRUGS IN THE PIPELINE FOR POTENTIAL USE WITH BBB TECHNOLOGY.....	73
BRAIN CANCER.....	74
<i>TABLE 10 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2015.....</i>	<i>74</i>
<i>TABLE 10 (CONTINUED).....</i>	<i>75</i>
<i>TABLE 10 (CONTINUED).....</i>	<i>76</i>
ANXIETY	76
<i>TABLE 11 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2015</i>	<i>76</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>77</i>
DEMENTIA	77
<i>TABLE 12 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2015.....</i>	<i>77</i>
<i>TABLE 12 (CONTINUED).....</i>	<i>78</i>
PARKINSON'S DISEASE.....	79
<i>TABLE 13 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2015.....</i>	<i>79</i>
DEPRESSION	79
<i>TABLE 14 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2015.....</i>	<i>80</i>
<i>TABLE 14 (CONTINUED).....</i>	<i>81</i>
PERSONALITY/PSYCHIATRIC DISORDERS	81
<i>TABLE 15 GLOBAL PIPELINE FOR OTHER PSYCHIATRIC DISORDERS, THROUGH 2015.....</i>	<i>82</i>
<i>TABLE 15 (CONTINUED).....</i>	<i>83</i>
SPINAL CORD INJURY.....	83
<i>TABLE 16 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2015.....</i>	<i>83</i>
ADDICTION DISORDERS	83
<i>TABLE 17 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2015.....</i>	<i>84</i>
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD).....	84
<i>TABLE 18 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER, THROUGH 2015</i>	<i>85</i>
SLEEP DISORDERS	85
<i>TABLE 19 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2015</i>	<i>85</i>
<i>TABLE 19 (CONTINUED).....</i>	<i>86</i>
CHAPTER FOUR: COMPANY PROFILES.....	87
ABLYNX NV	87
ABLYNX NV (CONTINUED)	88
ADENIOS, INC.	89
ALLON THERAPEUTICS, INC.....	89
ANGIOCHEM INC.	90

ANGIOCHEM INC. (CONTINUED)	91
ARMAGEN TECHNOLOGIES, INC.....	92
ARMAGEN TECHNOLOGIES, INC. (CONTINUED)	93
BIOASIS TECHNOLOGIES INC.....	94
BRAINCELLS INC	95
BRISTOL-MYERS SQUIBB.....	96
CAPSULATION PHARMA AG	96
CELLIAL TECHNOLOGIES.....	97
CYPRESS BIOSCIENCES, INC	97
CENERX BIOPHARMA, INC	98
CEPHALON INC	99
COGNITION PHARMACEUTICALS LLC.....	99
CYTOS BIOTECHNOLOGY AG	100
DIAMEDICA INC.	100
DAINIPPON SUMITOMO PHARMA (DSP) CO, LTD.	100
ENVIVO PHARMACEUTICALS, INC.	101
ELI LILLY AND COMPANY	102
GENZYME	103
FABRE-KRAMER PHARMACEUTICALS, INC.....	104
GERON CORPORATION	104
GERON CORPORATION (CONTINUED).....	105
INSIGHTEC, LTD.	106
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS)	107
IN CEREBRO.....	107
JANSSEN PHARMACEUTICA NV	108
H LUNDBECK A/S.....	108
H LUNDBECK A/S (CONTINUED).....	109
<i>TABLE 20 LUNDBECK'S CNS PIPELINE.....</i>	<i>110</i>
MEDGENESIS THERAPEUTIX, INC. (BIOVAIL LAB).....	110
MEDIMMUNE	111
MEDINVENT LLC	111
MITHRIDION, INC.	112
NEUROGENETIC PHARMACEUTICALS, INC.	113
NEUROVIVE PHARMACEUTICAL AB	113
NSGENE A/S.....	114
NEUREN PHARMACEUTICALS LTD.	115
OPTINOSE.....	115
OTSUKA AMERICA PHARMACEUTICAL, INC.	116
PROTHERAGEN, INC.	116
PFIZER.....	117
<i>TABLE 21 PFIZER'S CNS PIPELINE</i>	<i>118</i>
PHARMACO-CELL COMPANY LTD.....	118
PHARMIDEX	119
RAPTOR PHARMACEUTICAL CORP.....	120

ROCHE	121
SHIRE PLC	122
SANERON CCEL THERAPEUTICS, INC.	123
SOLVO BIOTECHNOLOGY	123
SPENCER PHARMACEUTICAL.....	124
SOVICELL GMBH.....	125
SYNAGEVA BIOPHARMA	126
TARGACEPT, INC.....	127
TETRAGENEX PHARMACEUTICALS, INC	128
TO-BBB TECHNOLOGIES BV.....	128
TRANSMOLECULAR INC.....	129
TTY BIOPHARM	130
UCB	131
VECT-HORUS.....	131
XENOPORT	132
XIGEN SA	133